Mangge Harald, Kneihsl Markus, Schnedl Wolfgang, Sendlhofer Gerald, Curcio Francesco, Domenis Rossana
Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, 8036 Graz, Austria.
Department of Neurology, Medical University of Graz, 8036 Graz, Austria.
Biomedicines. 2021 Sep 28;9(10):1342. doi: 10.3390/biomedicines9101342.
Understanding immune reactivity against SARS-CoV-2 is essential for coping with the COVID-19 pandemic. Herein, we discuss experiences and open questions about the complex immune responses to SARS-CoV-2. Some people react excellently without experiencing any clinical symptoms, they do not get sick, and they do not pass the virus on to anyone else ("sterilizing" immunity). Others produce antibodies and do not get COVID-19 but transmit the virus to others ("protective" immunity). Some people get sick but recover. A varying percentage develops respiratory failure, systemic symptoms, clotting disorders, cytokine storms, or multi-organ failure; they subsequently decease. Some develop long COVID, a new pathologic entity similar to fatigue syndrome or autoimmunity. In reality, COVID-19 is considered more of a systemic immune-vascular disease than a pulmonic disease, involving many tissues and the central nervous system. To fully comprehend the complex clinical manifestations, a profound understanding of the immune responses to SARS-CoV-2 is a good way to improve clinical management of COVID-19. Although neutralizing antibodies are an established approach to recognize an immune status, cellular immunity plays at least an equivalent or an even more important role. However, reliable methods to estimate the SARS-CoV-2-specific T cell capacity are not available for clinical routines. This deficit is important because an unknown percentage of people may exist with good memory T cell responsibility but a low number of or completely lacking peripheral antibodies against SARS-CoV-2. Apart from natural immune responses, vaccination against SARS-CoV-2 turned out to be very effective and much safer than naturally acquired immunity. Nevertheless, besides unwanted side effects of the currently available vector and mRNA preparations, concerns remain whether these vaccines will be strong enough to defeat the pandemic. Altogether, herein we discuss important questions, and try to give answers based on the current knowledge and preliminary data from our laboratories.
了解针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的免疫反应对于应对2019冠状病毒病(COVID-19)大流行至关重要。在此,我们讨论关于对SARS-CoV-2复杂免疫反应的经验和未解决的问题。有些人反应良好,没有出现任何临床症状,他们不会生病,也不会将病毒传染给其他人(“无菌”免疫)。其他人产生抗体,不会感染COVID-19,但会将病毒传染给其他人(“保护性”免疫)。有些人会生病但会康复。不同比例的人会发展为呼吸衰竭、全身症状、凝血障碍、细胞因子风暴或多器官衰竭;随后他们会死亡。有些人会患上“长新冠”,这是一种类似于疲劳综合征或自身免疫的新病理实体。实际上,COVID-19被认为更像是一种全身性免疫血管疾病,而非肺部疾病,它涉及许多组织和中枢神经系统。为了全面理解复杂的临床表现,深入了解对SARS-CoV-2的免疫反应是改善COVID-19临床管理的一个好方法。尽管中和抗体是识别免疫状态的既定方法,但细胞免疫至少发挥着同等重要甚至更重要的作用。然而,用于临床常规评估SARS-CoV-2特异性T细胞能力的可靠方法尚不存在。这一不足很重要,因为可能存在未知比例的人,他们具有良好的记忆T细胞功能,但针对SARS-CoV-2的外周抗体数量很少或完全缺乏。除了自然免疫反应外,针对SARS-CoV-2的疫苗接种被证明非常有效,而且比自然获得的免疫力安全得多。然而,除了目前可用的载体和信使核糖核酸(mRNA)制剂存在不良副作用外,人们仍担心这些疫苗是否足以战胜大流行。总之,在此我们讨论重要问题,并试图根据当前知识和我们实验室的初步数据给出答案。